GlassScriptPhysician profile
Michael P Gelatt
NPI 1477999233
$7,740.58
in general payments reported to CMS, 2019-2025
51 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,724 · 2020: $475 · 2022: $1,119 · 2023: $1,736 · 2024: $1,355 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,422.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.67 | 2019-2025 | |
| Novo Nordisk INC | $888.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $625.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $528.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $470.93 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $421.98 | 2019-2025 | |
| Astellas Pharma US INC | $344.96 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.80 | 2019-2025 | Jardiance |
| Allergan, INC. | $215.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $212.09 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Corium, LLC | $210.99 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.79 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $167.63 | 2022 | |
| Glaxosmithkline, LLC. | $135.32 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Alexion Pharmaceuticals, INC. | $129.00 | 2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gelatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.